Taysha Gene Therapies Q1 net loss widens on higher R&D costs

Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.

TSHA

0.00


Overview

  • U.S. gene therapy developer's net loss widened on higher R&D costs

  • Higher expenses driven by BLA-enabling manufacturing and clinical trial activity


Result Drivers

  • R&D SPENDING - Higher research and development expenses driven by BLA-enabling manufacturing initiatives and increased clinical trial activity for TSHA-102

  • ADMINISTRATIVE COSTS - General and administrative expenses rose due to higher compensation and commercial launch-readiness initiatives


Company press release: ID:nGNX7qYpmb


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Net Income

-$42.41 mln

Q1 Operating Expenses

$43.49 mln

Q1 Operating Income

-$43.49 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Taysha Gene Therapies Inc is $11.50, about 65.7% above its May 5 closing price of $6.94


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.